November 1 2016 Issue

1) School aged cognition in children exposed to levetiracetam, topiramate or sodium valproate2) What's Trending: Interview with David Spencer about his book titled: "Navigating life with epilepsy" 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Rebecca Bromley about her paper about school aged cognition in children exposed to levetiracetam, topiramate or sodium valproate. Dr. Ted Burns is interviewing Dr. David Spencer for our "What's Trending" feature of the week about his recently published Neurology Now book titled: "Navigating life with epilepsy." In the next part of the podcast Dr. Jeff Ratliff interviews Prof. Kailash Bhatia on the topic of "how to approach" dystonia.DISCLOSURES: Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).Dr. Bromley provided expert testimony regarding fetal valproate syndrome in the UK; although this case did not go to court and received research support from Epilepsy Research UK.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Spencer serves as Patient Page Editor for Neurology®, including past 2 years EMedicine, Chief Editor, Journal of Behavior and Brain Science, Associate Editor Neurology Now, Professional Advisory Board, including past 2 years Epilepsy Currents: Contributing editor; received honorariafrom NeuroPace Inc.; receives research support from NeuroPace, Inc., Upsher-Smith Laboratories, Inc., and Acorda; and was a consultant in a legal case. Prof. Bhatia serves as Co-Editor in Chief for Movement disorders Clinical Practice, serves as an Associate Editor for Movement Disorders, serves as an editorial board member of Therapeutic Advances in Neurological Disorders; received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceuticals Ltd, received honoraria from GlaxoSmithKline, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Ipsen Pharmaceuticals, Inc., MerzPharmaceuticals, LLC; receives royalties from the publication of Oxford Specialist Handbook of Parkinson's Disease and Other Movement Disorders, Marsdens book of Movement disorder, Lancet Neurology review article; receives research support from Wellcome Trust MRC strategic neurodegenerative disease initiative award, Parkinson's UK, Dystonia Coalition and The Bachmann-Strauss Foundation.